ANDA 89416, held by Abraxis Pharmaceuticals. Procainamide Hydrochloride.
As of Nov 21, 2026, ANDA 89416 (Procainamide Hydrochloride), held by Abraxis Pharmaceuticals, was first approved by FDA on Nov 17, 1986, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 17, 1986 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Procainamide Hydrochloride500MG/ML · injectable;injection | Procainamide Hydrochloride | Discontinued |
| Dec 30, 1991 | Supplement 6Labeling | Approved | None posted |
| Oct 28, 1988 | Supplement 1Labeling | Approved | None posted |
| Nov 17, 1986 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters